Biological characteristics of osteoporosis drugs: the effect of osteoblast–osteoclast coupling

키워드

참고문헌 (44)

1. F. Cosman, "Clinician’s Guide to Prevention and Treatment of Osteoporosis", Osteoporosis International, 25(10), pp.2359~2381 (2014), Springer Science and Business Media LLC[DOI]
2. Russel Burge, "Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005-2025", Journal of Bone and Mineral Research, 22(3), pp.465~475 (2007), Wiley[DOI]
3. Xiao Chen, "Osteoblast–osteoclast interactions", Connective Tissue Research, 59(2), pp.99~107 (2017), Informa UK Limited[DOI]
4. Xu Cao, "Targeting osteoclast-osteoblast communication", Nature Medicine, 17(11), pp.1344~1346 (2011), Springer Science and Business Media LLC[DOI]
5. E.R van Beek, "Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates", Bone, 33(5), pp.805~811 (2003), Elsevier BV[DOI]
6. Amin D, "Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis", J Lipid Res, 33, pp.1657~1663 (1992)
7. Cecile Itzstein, "The regulation of osteoclast function and bone resorption by small GTPases", Small GTPases, 2(3), pp.117~130 (2014), Informa UK Limited[DOI]
8. Ermond Van Beek, "The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen-Containing Bisphosphonates", Journal of Bone and Mineral Research, 14(5), pp.722~729 (1999), Wiley[DOI]
9. Wei Wei, "Ligand Activation of ERRα by Cholesterol Mediates Statin and Bisphosphonate Effects", Cell Metabolism, 23(3), pp.479~491 (2016), Elsevier BV[DOI]
10. Michael McClung, "Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday", The American Journal of Medicine, 126(1), pp.13~20 (2013), Elsevier BV[DOI]
11. Nicola Maruotti, "Bisphosphonates: effects on osteoblast", European Journal of Clinical Pharmacology, 68(7), pp.1013~1018 (2012), Springer Science and Business Media LLC[DOI]
12. K. E. Naylor, "Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density", Osteoporosis International, 29(6), pp.1407~1417 (2018), Springer Science and Business Media LLC[DOI]
13. L. Pederson, "Regulation of bone formation by osteoclasts involves Wnt", BMP signaling and the chemokine sphingosine-1-phosphate, 2008, pp.105(52), 20764~20769[DOI]
14. Roland Baron, "Denosumab and bisphosphonates: Different mechanisms of action and effects", Bone, 48(4), pp.677~692 (2011), Elsevier BV[DOI]
15. Michael R. McClung, "Denosumab in Postmenopausal Women with Low Bone Mineral Density", New England Journal of Medicine, 354(8), pp.821~831 (2006), Massachusetts Medical Society[DOI]
16. Steven R. Cummings, "Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis", New England Journal of Medicine, 361(8), pp.756~765 (2009), Massachusetts Medical Society[DOI]
17. Juliet E Compston, "Osteoporosis", The Lancet, 393(10169), pp.364~376 (2019), Elsevier BV[DOI]
18. Sohail A. Khan, "Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis", Journal of Bone and Mineral Research, 12(10), pp.1700~1707 (1997), Wiley[DOI]
19. N. B. Watts, "Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?", Osteoporosis International, 23(1), pp.327~337 (2012), Springer Science and Business Media LLC[DOI]
20. Joel S. Finkelstein, "Bone Mineral Density Changes during the Menopause Transition in a Multiethnic Cohort of Women", The Journal of Clinical Endocrinology & Metabolism, 93(3), pp.861~868 (2008), The Endocrine Society[DOI]
21. Sundeep Khosla, "Estrogen and the skeleton", Trends in Endocrinology & Metabolism, 23(11), pp.576~581 (2012), Elsevier BV[DOI]
22. Takashi Nakamura, "Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts", Cell, 130(5), pp.811~823 (2007), Elsevier BV[DOI]
23. Marta Martin-Millan, "The Estrogen Receptor-α in Osteoclasts Mediates the Protective Effects of Estrogens on Cancellous But Not Cortical Bone", Molecular Endocrinology, 24(2), pp.323~334 (2010), The Endocrine Society[DOI]
24. Guitty Eghbali-Fatourechi, "Role of RANK ligand in mediating increased bone resorption in early postmenopausal women", Journal of Clinical Investigation, 111(8), pp.1221~1230 (2003), American Society for Clinical Investigation[DOI]
25. Lorenz C. Hofbauer, "Estrogen Stimulates Gene Expression and Protein Production of Osteoprotegerin in Human Osteoblastic Cells*", Endocrinology, 140(9), pp.4367~4370 (1999), The Endocrine Society[DOI]
26. S. Kousteni, "Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors", Cell, 104(5), pp.719~730 (2001), Elsevier BV[DOI]
27. Maria Almeida, "Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual", Journal of Clinical Investigation, 123(1), pp.394~404 (2013), American Society for Clinical Investigation[DOI]
28. Chlebowski RT, "Continuous combined estrogen plus progestin and endometrial cancer: the Women’s Health Initiative randomized trial", J Natl Cancer Inst, 108, pp.djv350~ (2015)[DOI]
29. Cauley JA, "Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density<SUBTITLE>The Women's Health Initiative Randomized Trial<", SUBTITLE>, 2003, pp.290(13), 1729~1738[DOI]
30. Rossouw JE, "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial", JAMA: The Journal of the American Medical Association, 288(3), pp.321~333 (2002), American Medical Association (AMA)[DOI]
31. Anderson GL, "Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy", JAMA, 291(14), pp.1701~1712 (2004), American Medical Association (AMA)[DOI]
32. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel, "The 2017 hormone therapy position statement of The North American Menopause Society", Menopause, 24(7), pp.728~753 (2017), Ovid Technologies (Wolters Kluwer Health)[DOI]
33. James H. Pickar, "Tissue selective estrogen complex (TSEC)", Menopause, 25(9), pp.1033~1045 (2018), Ovid Technologies (Wolters Kluwer Health)[DOI]
34. Steven R. Cummings, "The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women", JAMA, 281(23), pp.2189~2197 (1999), American Medical Association (AMA)[DOI]
35. Musiliyu Musa, "Medicinal Chemistry and Emerging Strategies Applied to the Development of Selective Estrogen Receptor Modulators (SERMs)", Current Medicinal Chemistry, 14(11), pp.1249~1261 (2007), Bentham Science Publishers Ltd.[DOI]
36. Ettinger B, "Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial<", SUBTITLE>, 1999, pp.282(7), 637~645[DOI]
37. Stuart L Silverman, "Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial", Journal of Bone and Mineral Research, 23(12), pp.1923~1934 (2008), Wiley[DOI]
38. Derya Aslan, "Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans", Scandinavian Journal of Clinical and Laboratory Investigation, 72(1), pp.14~22 (2011), Informa UK Limited[DOI]
39. Rachel M. Locklin, "Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone", Journal of Cellular Biochemistry, 89(1), pp.180~190 (2003), Wiley[DOI]
40. Robert M. Neer, "Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis", New England Journal of Medicine, 344(19), pp.1434~1441 (2001), Massachusetts Medical Society[DOI]
41. Paul D. Miller, "Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis", JAMA, 316(7), pp.722~733 (2016), American Medical Association (AMA)[DOI]
42. John L. Vahle, "Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety", Toxicologic Pathology, 30(3), pp.312~321 (2016), SAGE Publications[DOI]
43. Johannes Pleiner-Duxneuner, "Treatment of Osteoporosis with Parathyroid Hormone and Teriparatide", Calcified Tissue International, 84(3), pp.159~170 (2009), Springer Science and Business Media LLC[DOI]
44. Kenneth G. Saag, "Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis", New England Journal of Medicine, 377(15), pp.1417~1427 (2017), Massachusetts Medical Society[DOI]